PER-012-04已完成未知
STUDY PHASE III, MULTICENTER, INTERNATIONAL, RANDOMIZED, SUSPENSION, TO EVALUATE THE SAFETY AND EFFICACY OF BMS-188667 IN CHILDREN AND ADOLESCENTS WITH RHEUMATOID ARTHRITIS YOUTH POLIARTICULAR (ARJ)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Diagnosis of juvenile rheumatoid arthritis or juvenile idiopathic arthritis;
- •Current active arthritis;
- •Failed treatment with at least one disease modifying antirheumatic drug (DMARD);
- •Subjects should discontinue the use of any DMARD other than methotrexate before the first dose of study medication
排除标准
- •Presence of infection or a history of frequent acute or chronic infections;
- •Joint replacement surgery required during the study or history of surgery in more than 5 joints;
- •Live vaccines within 3 months of the first dose of the study medication;
- •Severe unresolved bacterial infection or chronic bacterial infection;
- •Subjects who currently have intermittent fever due to ARJ / JIA, rheumatoid exanthema, hepato-splenomegaly, pleuritis, pericarditis or macrophage activation syndrome.
研究者
相似试验
进行中（未招募）
不适用
Estudio de fase III, multicéntrico, internacional, aleatorizado, de grupos paralelos, doble ciego, de seguridad cardiovascular de BI 10773 (10 mgy 25 mg administrados por vía oral una vez al día) comparado con el tratamiento habitual en pacientes con diabetes mellitus de tipo 2 con un riesgo cardiovascular aumentadoA Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.EUCTR2009-016178-33-ESBoehringer Ingelheim Pharmaceuticals, España S.A.4,000
进行中（未招募）
不适用
Estudio de fase III, internacional, multicéntrico, aleatorizado, doble ciego, controlado con placebo de doxorrubicina más palifosfamida-tris comparado con doxorrubicina más placebo en pacientes con sarcoma de tejido blando metastásico en primera línea. - PICASSO IIIsarcoma de tejido blando metastásicoEUCTR2010-019866-96-ESZIOPHARM Oncology Inc424
进行中（未招募）
不适用
Ensayo en fase III multicéntrico, internacional, abierto con dos grupos de tratamiento que evaluará bevacizumab adyuvante en el cáncer de mama triple negativo.An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. - BEATRICEEUCTR2007-001128-11-ESF. Hoffmann-La Roche Ltd.2,530
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).EUCTR2017-004262-95-GBSanten SAS380
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).Open-Angle Glaucoma or Ocular HypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-004262-95-EESanten SAS380